Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELVN Enliven Treateutics

Trading 08-25 15:15:33 EDT

60.75

-0.40

-0.65%

High62.00	Low60.57	Vol300.80K
Open61.90	D1 Closing61.15	Amplitude2.34%
Mkt Cap4.45B	Tradable Cap3.75B	Total Shares73.27M
T/O18.42M	T/O Rate0.49%	Tradable Shares61.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":60.75,"timestamp":1787685326706,"preClose":61.15,"halted":0,"volume":300804,"delay":0,"changeRate":-0.006541291905151244,"floatShares":61725902,"shares":73270761,"eps":-1.67535,"marketStatus":"Trading","change":-0.4,"latestTime":"08-25 15:15:33 EDT","open":61.9,"high":62,"low":60.57,"amount":18418696.971024,"amplitude":0.023385,"askPrice":60.79,"askSize":230,"bidPrice":60.59,"bidSize":206,"shortable":3,"etf":0,"ttmEps":-1.67535,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":61.15,"preHourTrading":{"tag":"盘前","latestPrice":62.79,"preClose":61.15,"latestTime":"09:06 EDT","volume":978,"amount":59998.328352,"timestamp":1787663170172,"change":1.64,"changeRate":0.026819,"amplitude":0.029272},"postHourTrading":{"tag":"盘后","latestPrice":61.5,"preClose":61.15,"latestTime":"19:30 EDT","volume":179064,"amount":10950252.52,"timestamp":1787614206861,"change":0.35,"changeRate":0.005724,"amplitude":0.005724},"volumeRatio":0.389168,"impliedVol":0.5885,"impliedVolPercentile":0.3785},"requestUrl":"/m/hq/s/ELVN/wiki","defaultTab":"wiki","newsList":[{"id":"2661784220","title":"Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661784220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661784220?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:20","pubTimestamp":1787566808,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enliven Therapeutics (ELVN), Argenx Se (ARGX) and Aq...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-enliven-therapeutics-elvn-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-enliven-therapeutics-elvn-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","LU2324357040.USD","LU0109394709.USD","BK4588","IE00BJT1NW94.SGD","BK4505","BK4139","IE00B2B36J28.USD","IE0009355771.USD","LU0320765992.SGD","BK4585","IE0002141913.USD","IE00BFTCPJ56.SGD","ARGX","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","IE0034235188.USD","LU1983260115.SGD","TBXU","BK4007","FMED","IBB","LU0823416689.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660047333","title":"Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2660047333","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660047333?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:17","pubTimestamp":1787170628,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics CMO Helen Louise Collins reports disposal of 5,000 common shares worth $293,612.17Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDLbx8wnX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469285","title":"Enliven Therapeutics, Inc. : Mizuho Raises Target Price to $73 from $62","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469285?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:34","pubTimestamp":1787049270,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F055:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469656","title":"Enliven initiated with an Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469656","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469656?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:15","pubTimestamp":1787048149,"startTime":"0","endTime":"0","summary":"William Blair initiated coverage of Enliven (ELVN) with an Outperform rating. The company is advancing ELVN-001, a “highly selective and efficaciou...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-initiated-with-an-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-initiated-with-an-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660346624","title":"Enliven Therapeutics, Inc. : William Blair Initiates Coverage with Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2660346624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660346624?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:05","pubTimestamp":1787047516,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F0HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660488079","title":"U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2660488079","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660488079?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:16","pubTimestamp":1786954612,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell TechnologiesAug 17 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4N44E0FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGT","URAN","COP","AMLX","CLYM","DUK","EQT","XLE","RSPS","EAT","CPT","DNTH","AHR","BMRN","EXE","CVX","PXE","CHRD","ALAB","BILT","DCH","CBRE","ESS","RDVY","TDV","CHPS","TINY","ELVN","EOG","AVB","BYND","DAVE","AMAT","AMTM","DVN","FHLC","AEP","DLTR","APA","CRWD","DELL","AVBP","CCAP","FANG","ELS","APP","ABBV","HON","BCSF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165205","title":"Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165205","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165205?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:36","pubTimestamp":1786635368,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Dara Azar reiterated a Buy rating on Enliven Therapeutics today and set a price target of $82.00. According to TipRanks, Az...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/enliven-therapeutics-elvn-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/enliven-therapeutics-elvn-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4139","BK4007","BK4539","ELVN","SF","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657776664","title":"Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2657776664","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657776664?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:18","pubTimestamp":1786061923,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics director Mika K. Derynck sells USD 9.56 million in common sharesEnliven Therapeutics director Mika K. Derynck sold 158,795 shares on Aug. 4 at a weighted average price of $60.21.T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL8myvFk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636920","title":"Stifel Nicolaus Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636920","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636920?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017642,"startTime":"0","endTime":"0","summary":"In a report released today, Dara Azar from Stifel Nicolaus maintained a Buy rating on Enliven Therapeutics, with a price target of $82.00. Accordin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-enliven-therapeutics-elvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-enliven-therapeutics-elvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","SF","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657331716","title":"Climb Bio Q2 Net Loss Widens on Pipeline Advancement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657331716","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657331716?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:29","pubTimestamp":1786015790,"startTime":"0","endTime":"0","summary":"Climb Bio Q2 net loss widens on pipeline advancementOverviewUS biotechnology firm's Q2 net loss widened yr/yr as operating expenses increasedCompany completed $110 mln private placement, extending cas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","CLYM","IBRN","BK4139","BK4007","TYRA","DNTH","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638230","title":"Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638230","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638230?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:10","pubTimestamp":1786014603,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Q2 revenue beats analyst estimatesOverviewU.S. biopharma's Q2 revenue fell yr/yr but beat analyst expectationsNet loss for Q2 widened and missed analyst estimatesCompany reaffirme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK4007","ACRS","BK0028","BK4139","ELVN","BK0239","300485","VNDA","BK0012","XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657502959","title":"Enliven Therapeutics, Inc. : Jefferies Raises Target Price to $69 from $59","url":"https://stock-news.laohu8.com/highlight/detail?id=2657502959","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657502959?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:08","pubTimestamp":1785996483,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4430RX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657503774","title":"Enliven Therapeutics, Inc. : Guggenheim Cuts Target Price to $78 from $80","url":"https://stock-news.laohu8.com/highlight/detail?id=2657503774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657503774?lang=en_us&edition=fundamental","pubTime":"2026-08-06 10:35","pubTimestamp":1785983710,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4421YG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578328","title":"Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578328","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578328?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:18","pubTimestamp":1785961100,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Q2 net loss widens on higher expensesOverviewUS biopharmaceutical firm's Q2 net loss widened yr/yr as operating expenses increasedCompany announced positive Phase 1 clinical data ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","DNTH","BK4007","TYRA","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578318","title":"Enliven Net Loss Widens 28.2% to $32.5 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578318","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578318?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:16","pubTimestamp":1785960990,"startTime":"0","endTime":"0","summary":"Enliven net loss widens 28.2% to $32.5 million in Q2 FY26Enliven Therapeutics posted a Q2 net loss of USD 32.49 million, worsening from USD 25.34 million a year earlier.R&D expenses climbed to USD 29 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL5YNCp6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653785228","title":"Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 262,213 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2653785228","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653785228?lang=en_us&edition=fundamental","pubTime":"2026-07-22 05:23","pubTimestamp":1784669026,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics CMO Helen Louise Collins disposes of USD 262,213 in common sharesEnliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares at $2.48 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL34VvSd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 262,213 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650915837","title":"13D Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2650915837","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650915837?lang=en_us&edition=fundamental","pubTime":"2026-07-11 07:26","pubTimestamp":1783725960,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LOCO","ORKA","NNBR","BK4209","BK4023","BK4007","ELVN","NCNO","BK4161","BK4139","ALVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650923733","title":"Enliven price target raised to $65 from $56 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2650923733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650923733?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:10","pubTimestamp":1783591844,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns raised the firm’s price target on Enliven (ELVN) to $65 from $56 and keeps a Buy rating on the shares after ra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-price-target-raised-to-65-from-56-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-price-target-raised-to-65-from-56-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650923323","title":"Enliven Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $64 from $56","url":"https://stock-news.laohu8.com/highlight/detail?id=2650923323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650923323?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:07","pubTimestamp":1783591652,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nAZN4T6UVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650511919","title":"Enliven Therapeutics Director Lori Anne Kunkel Disposes of USD 504,256 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650511919","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650511919?lang=en_us&edition=fundamental","pubTime":"2026-07-09 05:18","pubTimestamp":1783545494,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics director Lori Anne Kunkel disposes of USD 504,256 common sharesEnliven Therapeutics director Lori Anne Kunkel sold 10,000 shares on July 6, 2026.Sales priced at $49.98 to $50.84 p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL9dgyvq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Enliven Therapeutics Director Lori Anne Kunkel Disposes of USD 504,256 Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.enliventherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0271},{"period":"1month","weight":0.1549},{"period":"3month","weight":0.4378},{"period":"6month","weight":1.0885},{"period":"1year","weight":1.9329},{"period":"ytd","weight":2.9708}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.026887},{"month":2,"riseRate":0.666667,"avgChangeRate":0.05311},{"month":3,"riseRate":0.666667,"avgChangeRate":0.048411},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.063791},{"month":5,"riseRate":0.285714,"avgChangeRate":0.136586},{"month":6,"riseRate":0.857143,"avgChangeRate":0.068871},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.079074},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.014898},{"month":9,"riseRate":0.5,"avgChangeRate":0.118476},{"month":10,"riseRate":0.5,"avgChangeRate":0.124766},{"month":11,"riseRate":0.166667,"avgChangeRate":0.036396},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.10748}],"exchange":"NASDAQ","name":"Enliven Treateutics","nameEN":"Enliven Treateutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Enliven Treateutics,ELVN,Enliven Treateutics股票,Enliven Treateutics股票老虎,Enliven Treateutics股票老虎国际,Enliven Treateutics行情,Enliven Treateutics股票行情,Enliven Treateutics股价,Enliven Treateutics股市,Enliven Treateutics股票价格,Enliven Treateutics股票交易,Enliven Treateutics股票购买,Enliven Treateutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction